Lack of an effect of pioglitazone or glipizide on lipoprotein-associated phospholipase A2 in type 2 diabetes

Ananda Basu, Michael Dennis Jensen, Frances McCann, Debashis Nandy, Debabrata Mukhopadhyay, Joseph P. McConnell, Robert A. Rizza

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Objective: To study the effects of pioglitazone, a peroxisome proliferator-activated receptor-γ agonist with vascular beneficial effects, and glipizide, an insulin secretagogue, on novel inflammatory vascular risk markers in subjects with and without type 2 diabetes. Methods: We studied 11 subjects without diabetes and 19 matched subjects with diabetes. The subjects with diabetes were randomly assigned to receive either 45 mg daily of pioglitazone (N = 8) or 10 mg daily of glipizide (N = 11) (median dose) for 12 weeks. Lipoprotein-associated phospholipase A2 (LpPLA2), vascular cell adhesion molecule (VCAM-1), intracellular adhesion molecule (ICAM-1), and e-selectin were measured by established techniques before and after therapy with either agent. The subjects without diabetes were studied only once. Results: The study subjects with diabetes had higher (P<0.05) LpPLA2, e-selectin, and VCAM-1 levels than did those without diabetes. ICAM-1 levels tended to be higher (P = 0.07) in the study subjects with than in those without diabetes. Neither pioglitazone nor glipizide therapy significantly altered LpPLA2 or VCAM-1 concentrations. While pioglitazone therapy reduced (P<0.05) e-selectin concentrations, glipizide therapy reduced (P<0.03) ICAM-1 concentrations. Conclusion: Type 2 diabetes is associated with elevated concentrations of the novel vascular risk marker LpPLA2 and inflammatory risk markers e-selectin and VCAM-1. Neither pioglitazone nor glipizide significantly altered LpPLA2, VCAM-1, or highly sensitive C-reactive protein levels after 12 weeks of therapy. In study subjects with type 2 diabetes, e-selectin concentrations declined significantly with pioglitazone therapy, whereas ICAM-1 concentrations decreased significantly with glipizide therapy.

Original languageEnglish (US)
Pages (from-to)147-152
Number of pages6
JournalEndocrine Practice
Volume13
Issue number2
StatePublished - Mar 2007

Fingerprint

pioglitazone
1-Alkyl-2-acetylglycerophosphocholine Esterase
Glipizide
Vascular Cell Adhesion Molecule-1
Type 2 Diabetes Mellitus
Selectins
Intercellular Adhesion Molecule-1
Blood Vessels
Therapeutics
Peroxisome Proliferator-Activated Receptors
C-Reactive Protein

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Lack of an effect of pioglitazone or glipizide on lipoprotein-associated phospholipase A2 in type 2 diabetes. / Basu, Ananda; Jensen, Michael Dennis; McCann, Frances; Nandy, Debashis; Mukhopadhyay, Debabrata; McConnell, Joseph P.; Rizza, Robert A.

In: Endocrine Practice, Vol. 13, No. 2, 03.2007, p. 147-152.

Research output: Contribution to journalArticle

Basu, Ananda ; Jensen, Michael Dennis ; McCann, Frances ; Nandy, Debashis ; Mukhopadhyay, Debabrata ; McConnell, Joseph P. ; Rizza, Robert A. / Lack of an effect of pioglitazone or glipizide on lipoprotein-associated phospholipase A2 in type 2 diabetes. In: Endocrine Practice. 2007 ; Vol. 13, No. 2. pp. 147-152.
@article{19df41a1f6534a26bbfbaf4a81555e48,
title = "Lack of an effect of pioglitazone or glipizide on lipoprotein-associated phospholipase A2 in type 2 diabetes",
abstract = "Objective: To study the effects of pioglitazone, a peroxisome proliferator-activated receptor-γ agonist with vascular beneficial effects, and glipizide, an insulin secretagogue, on novel inflammatory vascular risk markers in subjects with and without type 2 diabetes. Methods: We studied 11 subjects without diabetes and 19 matched subjects with diabetes. The subjects with diabetes were randomly assigned to receive either 45 mg daily of pioglitazone (N = 8) or 10 mg daily of glipizide (N = 11) (median dose) for 12 weeks. Lipoprotein-associated phospholipase A2 (LpPLA2), vascular cell adhesion molecule (VCAM-1), intracellular adhesion molecule (ICAM-1), and e-selectin were measured by established techniques before and after therapy with either agent. The subjects without diabetes were studied only once. Results: The study subjects with diabetes had higher (P<0.05) LpPLA2, e-selectin, and VCAM-1 levels than did those without diabetes. ICAM-1 levels tended to be higher (P = 0.07) in the study subjects with than in those without diabetes. Neither pioglitazone nor glipizide therapy significantly altered LpPLA2 or VCAM-1 concentrations. While pioglitazone therapy reduced (P<0.05) e-selectin concentrations, glipizide therapy reduced (P<0.03) ICAM-1 concentrations. Conclusion: Type 2 diabetes is associated with elevated concentrations of the novel vascular risk marker LpPLA2 and inflammatory risk markers e-selectin and VCAM-1. Neither pioglitazone nor glipizide significantly altered LpPLA2, VCAM-1, or highly sensitive C-reactive protein levels after 12 weeks of therapy. In study subjects with type 2 diabetes, e-selectin concentrations declined significantly with pioglitazone therapy, whereas ICAM-1 concentrations decreased significantly with glipizide therapy.",
author = "Ananda Basu and Jensen, {Michael Dennis} and Frances McCann and Debashis Nandy and Debabrata Mukhopadhyay and McConnell, {Joseph P.} and Rizza, {Robert A.}",
year = "2007",
month = "3",
language = "English (US)",
volume = "13",
pages = "147--152",
journal = "Endocrine Practice",
issn = "1530-891X",
publisher = "American Association of Clinical Endocrinology",
number = "2",

}

TY - JOUR

T1 - Lack of an effect of pioglitazone or glipizide on lipoprotein-associated phospholipase A2 in type 2 diabetes

AU - Basu, Ananda

AU - Jensen, Michael Dennis

AU - McCann, Frances

AU - Nandy, Debashis

AU - Mukhopadhyay, Debabrata

AU - McConnell, Joseph P.

AU - Rizza, Robert A.

PY - 2007/3

Y1 - 2007/3

N2 - Objective: To study the effects of pioglitazone, a peroxisome proliferator-activated receptor-γ agonist with vascular beneficial effects, and glipizide, an insulin secretagogue, on novel inflammatory vascular risk markers in subjects with and without type 2 diabetes. Methods: We studied 11 subjects without diabetes and 19 matched subjects with diabetes. The subjects with diabetes were randomly assigned to receive either 45 mg daily of pioglitazone (N = 8) or 10 mg daily of glipizide (N = 11) (median dose) for 12 weeks. Lipoprotein-associated phospholipase A2 (LpPLA2), vascular cell adhesion molecule (VCAM-1), intracellular adhesion molecule (ICAM-1), and e-selectin were measured by established techniques before and after therapy with either agent. The subjects without diabetes were studied only once. Results: The study subjects with diabetes had higher (P<0.05) LpPLA2, e-selectin, and VCAM-1 levels than did those without diabetes. ICAM-1 levels tended to be higher (P = 0.07) in the study subjects with than in those without diabetes. Neither pioglitazone nor glipizide therapy significantly altered LpPLA2 or VCAM-1 concentrations. While pioglitazone therapy reduced (P<0.05) e-selectin concentrations, glipizide therapy reduced (P<0.03) ICAM-1 concentrations. Conclusion: Type 2 diabetes is associated with elevated concentrations of the novel vascular risk marker LpPLA2 and inflammatory risk markers e-selectin and VCAM-1. Neither pioglitazone nor glipizide significantly altered LpPLA2, VCAM-1, or highly sensitive C-reactive protein levels after 12 weeks of therapy. In study subjects with type 2 diabetes, e-selectin concentrations declined significantly with pioglitazone therapy, whereas ICAM-1 concentrations decreased significantly with glipizide therapy.

AB - Objective: To study the effects of pioglitazone, a peroxisome proliferator-activated receptor-γ agonist with vascular beneficial effects, and glipizide, an insulin secretagogue, on novel inflammatory vascular risk markers in subjects with and without type 2 diabetes. Methods: We studied 11 subjects without diabetes and 19 matched subjects with diabetes. The subjects with diabetes were randomly assigned to receive either 45 mg daily of pioglitazone (N = 8) or 10 mg daily of glipizide (N = 11) (median dose) for 12 weeks. Lipoprotein-associated phospholipase A2 (LpPLA2), vascular cell adhesion molecule (VCAM-1), intracellular adhesion molecule (ICAM-1), and e-selectin were measured by established techniques before and after therapy with either agent. The subjects without diabetes were studied only once. Results: The study subjects with diabetes had higher (P<0.05) LpPLA2, e-selectin, and VCAM-1 levels than did those without diabetes. ICAM-1 levels tended to be higher (P = 0.07) in the study subjects with than in those without diabetes. Neither pioglitazone nor glipizide therapy significantly altered LpPLA2 or VCAM-1 concentrations. While pioglitazone therapy reduced (P<0.05) e-selectin concentrations, glipizide therapy reduced (P<0.03) ICAM-1 concentrations. Conclusion: Type 2 diabetes is associated with elevated concentrations of the novel vascular risk marker LpPLA2 and inflammatory risk markers e-selectin and VCAM-1. Neither pioglitazone nor glipizide significantly altered LpPLA2, VCAM-1, or highly sensitive C-reactive protein levels after 12 weeks of therapy. In study subjects with type 2 diabetes, e-selectin concentrations declined significantly with pioglitazone therapy, whereas ICAM-1 concentrations decreased significantly with glipizide therapy.

UR - http://www.scopus.com/inward/record.url?scp=34447294272&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34447294272&partnerID=8YFLogxK

M3 - Article

C2 - 17490928

AN - SCOPUS:34447294272

VL - 13

SP - 147

EP - 152

JO - Endocrine Practice

JF - Endocrine Practice

SN - 1530-891X

IS - 2

ER -